Diversified Trust Co Acquires 1,015 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Diversified Trust Co increased its ownership in Regeneron Pharmaceuticals by 35.3% during the second quarter, totaling 3,889 shares worth approximately $2.04 million.
• Regeneron reported earnings of $12.89 EPS for the last quarter, surpassing analysts' expectations by $4.46, with a revenue of $3.68 billion.
• The company also declared a quarterly dividend of $0.88, equating to an annualized payout of $3.52, and a dividend yield of 0.6%.

Diversified Trust Co grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 35.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,889 shares of the biopharmaceutical company's stock after purchasing an additional 1,015 shares during the period. Diversified Trust Co's holdings in Regeneron Pharmaceuticals were worth $2,042,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in REGN. Kingstone Capital Partners Texas LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $40,736,000. Grove Bank & Trust boosted its stake in shares of Regeneron Pharmaceuticals by 36.7% in the 2nd quarter. Grove Bank & Trust now owns 1,107 shares of the biopharmaceutical company's stock valued at $581,000 after purchasing an additional 297 shares in the last quarter. Baker Tilly Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 10.8% during the 2nd quarter. Baker Tilly Wealth Management LLC now owns 1,280 shares of the biopharmaceutical company's stock worth $672,000 after buying an additional 125 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in Regeneron Pharmaceuticals by 17.5% during the 2nd quarter. Exchange Traded Concepts LLC now owns 3,940 shares of the biopharmaceutical company's stock worth $2,068,000 after purchasing an additional 588 shares during the last quarter. Finally, Polianta Ltd bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $1,365,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $26.88 during trading hours on Tuesday, hitting $568.80. The stock had a trading volume of 705,725 shares, compared to its average volume of 1,096,574. The firm has a market capitalization of $60.29 billion, a PE ratio of 14.29, a PEG ratio of 1.98 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The stock has a fifty day moving average price of $568.27 and a 200 day moving average price of $573.48. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,080.00.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period in the previous year, the business earned $11.56 earnings per share. The business's revenue was up 3.6% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on REGN shares. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research report on Monday, August 11th. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. Guggenheim raised their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.